These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3290578)

  • 1. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
    J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
    J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of combination therapy with flutamide in patients relapsing after castration.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Monfette G; Emond J; Bergeron N
    Br J Urol; 1988 Apr; 61(4):341-6. PubMed ID: 3289676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.
    Labrie F; Dupont A; Cusan L; Manhès G; Bergeron N; Lacourcière Y; Pineault S; Bélanger A; Monfette G; Emond J
    J Steroid Biochem; 1989 Oct; 33(4B):817-21. PubMed ID: 2689788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.
    Labrie F; Dupont A; Bélanger A; Cusan L; Giguère M; Lacourcière Y; Luthy I; Bégin D; Labrie C; Simard J
    Cancer Metastasis Rev; 1987; 6(4):615-36. PubMed ID: 3327635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
    Moorjani S; Dupont A; Labrie F; Lupien PJ; Gagné C; Brun D; Giguère M; Bélanger A; Cusan L
    J Clin Endocrinol Metab; 1988 Feb; 66(2):314-22. PubMed ID: 3276721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.
    Labrie F; Dupont A; Cusan L; Gomez J; Emond J; Monfette G
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):943-50. PubMed ID: 2285608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival.
    Labrie F; Dupont A; Belanger A; Giguere M; Lacoursiere Y; Emond J; Monfette G; Bergeron V
    J Steroid Biochem; 1985 Nov; 23(5B):833-41. PubMed ID: 2934579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma.
    Dupont A; Labrie F; Giguere M; Borsanyi JP; Lacourciere Y; Bergeron N; Cusan L; Belanger A; Emond J
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):659-66. PubMed ID: 3289945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
    Lacoste D; Dubé D; Bélanger A; Labrie F
    Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
    Dupont A; Cusan L; Gomez JL; Koutsilieris M; Suburu R; Emond J; Labrie F
    Br J Urol; 1993 Nov; 72(5 Pt 1):629-34. PubMed ID: 10071551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
    Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
    Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
    Labrie F; Dupont A; Belanger A; Lachance R
    J Urol; 1987 Oct; 138(4):804-6. PubMed ID: 3309363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of flutamide action on prostatic and testicular functions in the rat.
    Marchetti B; Labrie F
    J Steroid Biochem; 1988 Jun; 29(6):691-8. PubMed ID: 2838689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 3-week treatment with [D-Trp6, des-Gly-NH10(2)]LHRH ethylamide, aminoglutethimide, ketoconazole or flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog.
    Lacoste D; Caron S; Bélanger A; Labrie F
    J Steroid Biochem; 1989 Aug; 33(2):233-42. PubMed ID: 2671505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
    St-Arnaud R; Lachance R; Kelly SJ; Belanger A; Dupont A; Labrie F
    Clin Endocrinol (Oxf); 1986 Jan; 24(1):21-30. PubMed ID: 3519004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.